Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Medicenna Therapeutics Corp is a biotechnology business based in the US. Medicenna Therapeutics shares (MDNA) are listed on the NASDAQ and all prices are listed in US Dollars. Medicenna Therapeutics employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$2.43|
|52-week range||$1.85 - $6.84|
|50-day moving average||$2.53|
|200-day moving average||$3.11|
|Wall St. target price||$10.13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.34|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-3.95%|
|1 month (2021-09-15)||-3.57%|
|3 months (2021-07-15)||-15.63%|
|6 months (2021-04-15)||-38.79%|
|1 year (2020-10-15)||-38.48%|
|2 years (2019-10-15)||170.90%|
|3 years (2018-10-12)||125.00%|
|5 years (2016-10-11)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-33.65%|
|Return on equity TTM||-59.44%|
|Market capitalisation||$136 million|
TTM: trailing 12 months
There are currently 238,935 Medicenna Therapeutics shares held short by investors – that's known as Medicenna Therapeutics's "short interest". This figure is 26.4% up from 188,996 last month.
There are a few different ways that this level of interest in shorting Medicenna Therapeutics shares can be evaluated.
Medicenna Therapeutics's "short interest ratio" (SIR) is the quantity of Medicenna Therapeutics shares currently shorted divided by the average quantity of Medicenna Therapeutics shares traded daily (recently around 103435.06493506). Medicenna Therapeutics's SIR currently stands at 2.31. In other words for every 100,000 Medicenna Therapeutics shares traded daily on the market, roughly 2310 shares are currently held short.
However Medicenna Therapeutics's short interest can also be evaluated against the total number of Medicenna Therapeutics shares, or, against the total number of tradable Medicenna Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medicenna Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Medicenna Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0064% of the tradable shares (for every 100,000 tradable Medicenna Therapeutics shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medicenna Therapeutics.
Find out more about how you can short Medicenna Therapeutics stock.
We're not expecting Medicenna Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Medicenna Therapeutics's shares have ranged in value from as little as $1.85 up to $6.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medicenna Therapeutics's is 0.5282. This would suggest that Medicenna Therapeutics's shares are less volatile than average (for this exchange).
Medicenna Therapeutics Corp. , a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.